Xeno Dynamics, an exoskeleton robotics company, announced the completion of a Series A financing round of over 100 million RMB, led by Source Code Capital.

Xeno Dynamics recently completed a Series A financing round of over RMB 100 million, led by Source Code Capital, with Cornerstone Capital and Yaotu Capital participating. Existing investor Pangu Ventures continued to increase its stake, and Mumian Capital served as the exclusive financial advisor. The proceeds will be used primarily for product R&D and market expansion. Xeno Dynamics had previously raised tens of millions of RMB in venture funding from Pangu Ventures, Clear Water Bay Startup Fund, and Zhongguancun Equity Trading Service Group.

Shenzhen Xeno Dynamics Technology Co., Ltd. is a leading domestic powered exoskeleton robotics company, integrating R&D, manufacturing, and sales. It is committed to delivering revolutionary products and solutions for healthcare, industrial production, sports, and consumer applications. Guided by a philosophy of pragmatic innovation and grounded in precise analysis of industry pain points, the company continues to deepen its technological expertise in powered exoskeleton robotics. At the same time, with rigorous scientific spirit and profound humanistic care, it puts human-centered design at the heart of every product, aiming to use robotics technology to genuinely benefit humanity and open new possibilities for healthier, better lives.

Xeno Dynamics' core team hails from renowned universities at home and abroad. Founder and Chairman Zhe Liang graduated from The Hong Kong University of Science and Technology, where he studied under renowned robotics expert Zexiang Li. Co-founder and General Manager Ren Dong studied under eminent orthopedic specialist Wen Yuan and worked in clinical practice for many years. Both co-founders bring deep industry resources in their respective fields.

The two co-founders noted that compared with traditional robotics, exoskeleton robotics represents an entirely new product category spanning numerous interdisciplinary fields. As wearable robots for the human body, human-robot interaction is particularly critical. Therefore, the company's R&D team focuses intensively on research into the wearer, encompassing human biomechanics, clinical medicine, ergonomics, and neuroelectrophysiology. Supported by massive human body data, products are designed for application scenarios across different industries.

The effects of exoskeleton robots on wearers fall into two categories: assistance and augmentation. Early exoskeleton research attempted to use complex robotic systems to support human load and improve the efficiency of loaded walking. However, these systems ultimately failed to achieve broad application due to their own heavy weight and inability to meet requirements for compatibility with human movement. Over the past decade, biomechanics research has played an increasingly prominent role in advancing exoskeleton technology. A central research direction has become determining what kind of assistance to provide, and when, to deliver substantive benefits to wearers. For example, the proposal of new human-machine hybrid dynamics models has provided theoretical foundations and methods for movement assistance. Meanwhile, supporting technologies essential to ensuring exoskeleton performance and safety — such as new lightweight materials, high-performance actuators, robust human-robot interaction control, and electronic power systems — have also advanced considerably. More cutting-edge explorations in brain-computer interfaces, neuromodulation, and electromyographic coupling are opening new directions for exoskeleton development.

The company's current products primarily serve individuals with declining motor function, focusing on assistance and treatment for aging populations, central and peripheral nerve injuries, and musculoskeletal disorders. It also provides solutions for human augmentation in specific environments and for sports assistance and protection.

Yangjie She of Source Code Capital said: "China has a large population suffering from stroke and various central nervous system injuries, with high incidence rates. Whether patients can regain normal mobility after recovery profoundly impacts their quality of life. Xeno Dynamics' products are highly original, addressing numerous clinical needs and pain points. While ensuring patient comfort and safety, they also significantly improve physicians' work efficiency, placing the company at the industry's leading edge. The team started from the needs of patients and doctors, spending five years refining their products — not rushing in the short term, patient for the long term. We look forward to Xeno Dynamics' products enabling people to live better lives."

Source Code Capital portfolio company Mech-Mind

announces completion of Series C financing of several hundred million RMB

led by Meituan, with existing investor Source Code Capital increasing its stake

Personal care brand Rocking Zoo announces completion

of two consecutive rounds totaling tens of millions of USD

Source Code Capital participated in both rounds

Legal tech company PowerLaw AI

announces completion of nearly RMB 60 million Series A financing

led by Source Code Capital

General-purpose intelligent chip design company

Biren Technology announces completion of Series B financing

with participation from Source Code Capital

Chocolate brand Daily Black

announces completion of over RMB 100 million Series A+ and Series B financing

Source Code Capital led the Series A+ round

Click "Read More" to view more Source Code Capital portfolio companies